Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric and oncology disorders. Its lead candidate, BNC210, is an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor designed for acute and chronic treatment of social anxiety disorder and post-traumatic stress disorder, addressing significant unmet medical needs where current treatments carry risks of sedation, cognitive impairment, and addiction. The company generates revenue through milestone payments and royalties from strategic partnerships, including a collaboration with Merck for α7 receptor modulators in cognitive disorders, while advancing cancer-focused programs through partnerships with entities like Carina Biotech. Neuphoria intends to build a focused U.S. commercial infrastructure for BNC210 if its clinical programs succeed, while pursuing partnership and licensing models for other indications and geographic markets.